Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SMTC, IWM, MRNS, ARDX, XBI, and represent 85.12% of Lion Point Capital's stock portfolio.
- Added to shares of these 10 stocks: IWM (+$17M), XBI, GERN, MIST, NBIX, JSPR, MIRM, MLYS, SNDX, RGNX.
- Started 7 new stock positions in GERN, JSPR, SPRB, MLYS, XBI, NBIX, RGNX.
- Reduced shares in these 9 stocks: SMTC (-$71M), Harpoon Therapeutics, Cymabay Therapeutics, BATL, ARDX, AMLX, AADI, MRNS, ACRS.
- Sold out of its positions in AADI, ACRS, AMLX, Cymabay Therapeutics, Harpoon Therapeutics.
- Lion Point Capital was a net seller of stock by $-47M.
- Lion Point Capital has $179M in assets under management (AUM), dropping by -10.45%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lion Point Capital
Lion Point Capital holds 31 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Semtech Corporation (SMTC) | 38.4 | $69M | -50% | 2.5M | 27.50 |
|
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 29.1 | $52M | +50% | 248k | 210.30 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 10.7 | $19M | 2.1M | 9.04 |
|
|
| Ardelyx (ARDX) | 4.3 | $7.6M | -9% | 1.0M | 7.30 |
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 2.7 | $4.7M | NEW | 50k | 94.89 |
|
| Milestone Pharmaceuticals (MIST) | 2.3 | $4.1M | +39% | 2.3M | 1.79 |
|
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.4 | $2.6M | 131k | 19.73 |
|
|
| Geron Corporation (GERN) | 1.1 | $2.0M | NEW | 600k | 3.30 |
|
| Insmed Com Par $.01 (INSM) | 1.1 | $1.9M | 70k | 27.13 |
|
|
| Fennec Pharmaceuticals (FENC) | 1.1 | $1.9M | +54% | 170k | 11.12 |
|
| Burgerfi International (BFI) | 0.9 | $1.6M | 2.7M | 0.58 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.9 | $1.5M | +88% | 65k | 23.80 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 0.8 | $1.4M | +3% | 83k | 16.89 |
|
| Mirum Pharmaceuticals Put Option (MIRM) | 0.6 | $1.1M | +233% | 45k | 25.12 |
|
| Bluebird Bio (BLUE) | 0.6 | $1.1M | +59% | 848k | 1.28 |
|
| Neurocrine Biosciences (NBIX) | 0.6 | $1.0M | NEW | 7.5k | 137.92 |
|
| Jasper Therapeutics Com New (JSPR) | 0.5 | $940k | NEW | 32k | 29.36 |
|
| Enphys Acquisition Corp Cl A Ord Shs (NFYS) | 0.5 | $845k | 78k | 10.82 |
|
|
| Mineralys Therapeutics (MLYS) | 0.4 | $775k | NEW | 60k | 12.91 |
|
| Humacyte (HUMA) | 0.4 | $731k | 235k | 3.11 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.4 | $685k | NEW | 33k | 21.07 |
|
| Travere Therapeutics Note 2.250% 3/0 (Principal) | 0.4 | $630k | 1.0M | 0.63 |
|
|
| Travere Therapeutics (TVTX) | 0.3 | $601k | 78k | 7.71 |
|
|
| Replimune Group (REPL) | 0.2 | $347k | 43k | 8.17 |
|
|
| Seres Therapeutics (MCRB) | 0.1 | $264k | 341k | 0.77 |
|
|
| Lumos Pharma (LUMO) | 0.1 | $256k | 91k | 2.82 |
|
|
| Battalion Oil Corp (BATL) | 0.1 | $113k | -91% | 20k | 5.66 |
|
| Burgerfi International *w Exp 12/16/202 (BFIIW) | 0.0 | $81k | 2.1M | 0.04 |
|
|
| Spruce Biosciences (SPRB) | 0.0 | $59k | NEW | 75k | 0.79 |
|
| Microsoft Corporation (MSFT) | 0.0 | $42k | 100.00 | 420.72 |
|
|
| Alphabet Cap Stk Cl C (GOOG) | 0.0 | $15k | 100.00 | 152.26 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2024 Q1 filed May 15, 2024
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022
- Lion Point Capital 2022 Q2 filed Aug. 15, 2022
- Lion Point Capital 2022 Q1 filed May 16, 2022
- Lion Point Capital 2021 Q4 filed Feb. 14, 2022
- Lion Point Capital 2021 Q3 filed Nov. 15, 2021
- Lion Point Capital 2021 Q2 filed Aug. 16, 2021
- Lion Point Capital 2021 Q1 restated filed May 19, 2021
- Lion Point Capital 2021 Q1 filed May 17, 2021
- Lion Point Capital 2020 Q4 filed Feb. 16, 2021
- Lion Point Capital 2020 Q3 filed Nov. 16, 2020